More than half of patients with pyoderma gangrenosum present with a relevant underlying disease, according to a recent study, with inflammatory bowel disease and arthritis the most frequently associated diseases. Relative to the reported literature, the pooled prevalence of arthritis and hematological malignancies is lower, while the pooled prevalence of solid malignancies is higher. Researchers performed a systematic literature review and meta-analysis of observational studies dated from 1823–2017. The quality of evidence was assessed using a modified Newcastle-Ottawa Scale. A meta-analysis was performed using random-effects models to estimate pooled prevalence rates with 95% confidence intervals. 21 eligible studies comprising 2,611 patients with pyoderma gangrenosum were included in the quantitative synthesis. They found:
- The overall random-effects pooled prevalence of associated systemic diseases was 56.8%.
- The leading underlying disease was inflammatory bowel disease (17.6%), followed by arthritis (12.8%), hematological malignancies (8.9%), and solid malignancies (7.4%).
- In 16.3% of cases, the onset of pyoderma gangrenosum was attributed to the pathergy phenomenon.
Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(4):479-487. doi:10.1007/s40257-018-0356-7.
This Week's Must Reads
Patient Motivations for Seeking Cosmetic Procedures, JAMA Dermatology; ePub 2018 Aug 15; Maisel, et al
Pathology Methods for Melanocytic Lesions Compared, JAMA Dermatology; ePub 2018 Aug 15; Onega, et al
Renal Transplant Rejection Linked with Risk of cSCC, Clin Exp Dermatol; ePub 2018 Jun 27; Puza, et al
Microneedling Treatment Improves Skin Aging, J Clin Aesthet Dermatol; 2018 Aug 1; Ablon
Rejuvenation Procedure Proves Safe and Effective , Lasers Surg Med; ePub 2018 Aug 8; Knight, Kautz
Must Reads in Rare Diseases
Pyoderma Gangrenosum and Underlying Diseases, Am J Clin Dermatol; 2018 Aug; Kridin, Cohen, et al
Mohs Surgery Effective for Atypical Fibroxanthoma, J Am Acad Dermatol; ePub 2018 Jul 5; Tolkachjov, et al
FDA Approves Rituxan for Pemphigus Vulgaris, Genentech Web site; 2018 Jun 7
Climate, Pollution, and Pemphigus Associated, Clin Exp Dermatol; ePub 2018 Jun 1; Ren, et al
Klippel-Trenaunay Syndrome and Quality of Life, J Am Acad Dermatol; ePub 2018 Jun 5; Harvey, et al